Trump's new tariffs threaten EU trade deal with pharma and auto exemptions in focus

MacroGeopolitics Impact 4
โดย Seeking Alpha·Read original
Summary · why it matters

President Trump announced new U.S. tariffs of 10% to 12.5% on goods from most trading partners, raising questions about the recently negotiated trade deal with the European Union. Seeking Alpha analysts note that pharmaceuticals, heavily imported from the EU and including generic medications, are a key target, potentially affecting firms like Novo Nordisk, Roche, AstraZeneca, and Bayer. The EU deal, locked into EU law with a 15% rate, has not been ratified by the U.S. Senate and could still be changed, with a December 31 deadline for the U.S. to reduce metal tariffs to 15% seen as a critical test. Analysts also warn that additional tariffs on the EU could follow a billion-dollar fine against Alphabet, and that investor focus may shift to Middle East conflicts rather than trade war volatility.

Impact on stocks 5

Biotech & Genomic Medicine▼ · 2 stocks
AstraZeneca PLC
AZN
▼ NegativeTariffrelevance

Pharmaceuticals are a key target of new tariffs, and AstraZeneca is a major EU pharma exporter.

Novo Nordisk A/S
NOV
▼ NegativeTariffrelevance

Pharmaceuticals are a key target of new tariffs, and Novo Nordisk is a major EU pharma exporter.

Health Care▼ · 2 stocks
Bayer AG NA
BAYN
▼ NegativeTariffrelevance

Pharmaceuticals are a key target of new tariffs, and Bayer is a major EU pharma exporter.

Roche Holding AG
ROP
▼ NegativeTariffrelevance

Pharmaceuticals are a key target of new tariffs, and Roche is a major EU pharma exporter.

Artificial Intelligence▼ · 1 stocks
Alphabet Inc Class C
GOOG
▼ NegativeTariffrelevance

Article mentions a billion-dollar fine against Alphabet could trigger additional EU tariffs.

© 2026 MarketDXNews